Angiotensin II receptors from peritransplantation through first-year post-transplantation and the risk of transplant coronary artery disease.
OBJECTIVE
We evaluated whether the angiotensin II (Ang II) receptors from perioperation through one-year post-transplantation predict the transplant coronary artery disease (TCAD) progression.


BACKGROUND
The role of Ang II receptors (type 1: AT(1)R; type 2: AT(2)R) in TCAD is uncertain.


METHODS
We investigated 28 heart donors and the corresponding recipients. The levels of AT(1)R and AT(2)R messenger ribonucleic acid (mRNA) were examined in lymphocytes from the donor spleen and in the donor heart at one-week and one-year posttransplantation to determine their association with the progression of TCAD, measured as changes in maximal intimal thickness (CMIT) and plaque volume (CPV) by intravascular ultrasound (IVUS) examinations.


RESULTS
The AT(1)R mRNA in lymphocytes from the donor spleen (CMIT: r = 0.73, p < 0.0001; CPV: r = 0.69, p < 0.0001) and in the donor hearts at one-week (CMIT: r = 0.52, p = 0.005; CPV: r = 0.56, p = 0.002) and at one-year (CMIT: r = 0.63, p < 0.0001; CPV: r = 0.43, p = 0.004) post-transplantation along with AT(2)R mRNA in the donor hearts at one-year post-transplantation (CMIT: r = 0.3, p < 0.0001; CPV: r = 0.53, p = 0.009) were univariate predictors, whereas AT(1)R mRNA in lymphocytes and in the donor hearts at one-year post-transplantation proved to be multivariate predictors of the progression of TCAD.


CONCLUSIONS
These data suggest a role for Ang II receptors in the pathogenesis of TCAD and support a novel concept that TCAD may have its origin in the donor per se and may be modulated by the recipient's inherent biological factors.
Yousufuddin
Mohammed
M
Department of Cardiovascular Medicine, Kaufman Center for Heart Failure, Cleveland Clinic Foundation, Ohio 4195, USA.
Cook
Daniel J
DJ
Starling
Randall C
RC
Abdo
Ashraf
A
Paul
Philip
P
Tuzcu
E Murat
EM
Ratliff
Norman B
NB
McCarthy
Patrick M
PM
Young
James B
JB
Yamani
Mohamad H
MH
D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001706:Biopsy; D003324:Coronary Artery Disease / Q000453:epidemiology* / Q000209:etiology* / Q000378:metabolism; D003331:Coronary Vessels / Q000000981:diagnostic imaging / Q000378:metabolism / Q000473:pathology; D018450:Disease Progression; D005260:Female; D005455:Fluorescent Antibody Technique; D005500:Follow-Up Studies; D006333:Heart Failure / Q000188:drug therapy / Q000378:metabolism / Q000601:surgery; D016027:Heart Transplantation; D006801:Humans; D008214:Lymphocytes / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011183:Postoperative Complications / Q000453:epidemiology / Q000209:etiology / Q000378:metabolism; D011237:Predictive Value of Tests; D012333:RNA, Messenger / Q000378:metabolism; D044140:Receptor, Angiotensin, Type 1 / Q000096:biosynthesis; D011945:Receptors, Angiotensin / Q000096:biosynthesis*; D012307:Risk Factors; D014019:Tissue Donors; D016896:Treatment Outcome; D017539:Tunica Intima / Q000000981:diagnostic imaging / Q000378:metabolism / Q000473:pathology; D018084:Ultrasonography, Interventional
D000806:Angiotensin-Converting Enzyme Inhibitors; D012333:RNA, Messenger; D044140:Receptor, Angiotensin, Type 1; D011945:Receptors, Angiotensin